Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Ascendis Pharma A/S has resubmitted its NDA for TransCon PTH to the FDA for treating hypoparathyroidism. The resubmission follows a Type A meeting with the FDA and is based on positive clinical trial results and a new manufacturing control strategy. TransCon PTH has shown significant health improvements in trials and has received a positive CHMP opinion in the EU, with an EC decision expected soon.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:11 pm

Over the past 3 months, 7 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock, with 5 being somewhat bullish and 2 indifferent. The average 12-month price target for Ascendis Pharma is $150.14, which has increased by 9.59% over the past month.

Portfolio Pulse from Benzinga Insights

November 09, 2023 | 2:00 pm

Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $113 to $116.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:57 pm

Ascendis Pharma (NASDAQ:ASND) reported Q3 earnings, missing estimated earnings by 13.82% with an EPS of $-3.13 versus an estimate of $-2.75. However, revenue was up $36.87 million from the same period last year. Last quarter, the company beat EPS estimates which led to a 4.24% increase in the share price the next day.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 9:15 pm

Ascendis Pharma (NASDAQ:ASND) reported Q3 2023 losses of $(3.13) per share, missing the analyst consensus estimate of $(2.75) by 13.82%. This is a 2.62% decrease over losses from the same period last year. The company also reported quarterly sales of $52.28 million, missing the analyst consensus estimate of $52.70 million by 0.79%. However, this is a 239.19% increase over sales from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 07, 2023 | 9:11 pm

Ascendis Pharma (NASDAQ:ASND) is set to release its latest quarterly earnings report on November 7, 2023. Analysts estimate an earnings per share (EPS) of $-2.75. The company's past performance shows a pattern of beating EPS estimates, which has often led to an increase in share price. However, the stock has been down 23.91% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 4:00 pm

Ascendis Pharma A/S (NASDAQ:ASND) plans to report its Q3 2023 financial results and provide a business update on November 7, 2023. The company also announced its intention to resubmit its NDA for TransCon PTH for adults with hypoparathyroidism to the FDA before mid-November 2023. A conference call and webcast will be hosted on the same day to discuss the financial results and operations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:39 pm

Ascendis Pharma A/S (NASDAQ:ASND) presented updated and new data from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ at ESMO 2023. The data showed clinical responses with TransCon IL-2 β⁄γ as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy. The company continues enrollment in indication-specific cohorts for Phase 2 portion of the IL-Believe Trial.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:32 pm

Ascendis Pharma has presented 52-week results from the Phase 3 PaTHway Trial at ASBMR 2023. The results showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms. Bone turnover markers trended toward the normal reference ranges for sex and menopausal status and corresponded to smaller changes in bone mineral density (BMD) through Week 52.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:03 pm

Ascendis Pharma (NASDAQ:ASND) has received 10 analyst ratings in the last quarter, with 4 somewhat bullish and 6 indifferent. The company's average 12-month price target is $128.8, which has increased by 5.14% over the past month.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.